# Megatrends One Year Later – #11: Longevity Science – What I Predicted, and What’s Actually Happening
By 

## Article Content
“The future is not just extending lifespan, but our healthspan, by treating aging itself.” - Futurist Jim Carroll One year ago, in July 2025, I published Megatrend #11: Longevity Science as part of my 30 Megatrends series. Time to grade myself. Here's how I framed it in the original post: Nobody wants to get old. Everybody will. The age-old dilemma, if you pardon the pun. But lifespan extension through regenerative medicine, genetic therapies, and anti-aging technologies is creating new markets and challenging our assumptions about career timelines, retirement, and generational planning. The focus of this science has fundamentally shifted from merely extending lifespan to enhancing healthspan — the period of life spent in good health, free from chronic disease and disability. This paradigm shift recognizes that adding years to life has little value without maintaining quality of life and functional independence. So how's the aging-biology story holding up a year later? Better than "holding up" — it's accelerating, and on more fronts than I expected. Senolytics, the drugs that clear out senescent "zombie" cells, are now in more than 80 human trials worldwide, and the dasatinib-plus-quercetin combination just posted real Phase 2 results in chronic kidney disease patients — measurable improvement, not just biomarker noise. Epigenetic reprogramming — resetting cells to a younger state using Yamanaka factors — crossed from mouse studies into people this year. Life Biosciences got FDA clearance in January 2026 to begin Phase 1 human trials of its partial reprogramming therapy for a form of vision loss, and Retro Biosciences started dosing its first human patients with RTR242. Two years ago this was theoretical. Now it's in arms. The pillars I flagged as further behind are catching up faster than expected too. Telomere biology and mitochondrial health — the ones I said were still preclinical — aren't anymore: Klotho gene therapy, once a Yale mouse-longevity story, is now in multiple human safety trials testing cognition and healthspan in healthy adults, and Cornell's mitochondria-targeting peptide (SS-31) is deep into Phase II/III work while a related peptide, MOTS-c, entered its own Phase 2a human trial for metabolic aging in 2026. Verdict: Nailed it, and it's moving faster than the one-year mark usually allows. Every pillar I named — senescence, reprogramming, telomeres, mitochondria — now has a human trial attached to its name. The "longevity divide" I warned about is still the open question: none of this is priced for the average pension yet.

---
Source: https://jimcarroll.com/2026/08/megatrends-one-year-later-11-longevity-science/